Publisher's Synopsis
This book delves into the management of hepatocellular carcinoma (HCC) in low to middle-income countries. Shockingly, a projected 1.3 million people are at risk of dying from liver cancer by 2040, marking a 56.4% increase from 2020. HCC cases and deaths are expected to rise by over 50% in the next two decades.
The book discusses HCC management in low to middle-income countries with limited healthcare budgets and resources as the cost of therapeutic options for HCC, such as liver resection, transplantation, ablative therapies, transarterial embolotherapy/radiotherapy, systemic therapy, and palliative care vary significantly and can be substantial.
The book also emphasizes the role of the prevention of HCC. It is suitable for specialists in surgical oncology, medical oncology, radiation oncology, hepatology, gastroenterology, interventional radiology and surgery. It is also relevant for specialists in general medicine, public health, epidemiology, family medicine besides medical students, trainees and specialized nurses.
It aligns with UN SDG 3 - Good Health and Well-Being.
